Who are Amplyx's investors?

Amplyx's investors include BioBrit, Golden Seeds, Keiretsu Forum, Pappas Capital, Sofinnova Ventures, 3x5 Partners, Arix Bioscience, Lundbeckfonden Ventures and 3 more.

Amplyx

14 known investors

Find your way into Amplyx

Developing a new class of antifungal medicine to overcome limitations of current therapies.

Investors · 14

BioBritlisted by BioBritLa Jolla

Golden Seedslisted by Golden SeedsFlushing · $250K – $2M

How we know: Golden Seeds's portfolio page · Not right? Tell us

Keiretsu Forumlisted by Keiretsu ForumSan Francisco East Bay · $250K – $2M

How we know: Keiretsu Forum's portfolio page · Not right? Tell us

Pappas Capitallisted by Pappas CapitalDurham

How we know: Pappas Capital's portfolio page · Not right? Tell us

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · prnewswire.com · the VCSheet dataset · Not right? Tell us

3x5 PartnersreportedPortland

How we know: biospace.com · Not right? Tell us

Arix BiosciencereportedLondon

How we know: biospace.com · Not right? Tell us

Lundbeckfonden VenturesreportedKøbenhavn

How we know: biospace.com · Not right? Tell us

New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40M

How we know: biospace.com · Not right? Tell us

Pappas CapitalreportedResearch Triangle Park · $100K – $6M

How we know: biospace.com · Not right? Tell us

RiverVest Venture PartnersreportedSt. Louis · $500K – $3M

How we know: biospace.com · Not right? Tell us

Also in the syndicate · 3

BioMed VenturesPfizerSofinnova Investmentlead

Funding

SEC filings, press & company announcements

Undisclosed amountSeries C extensionMay 2020
Sofinnova Investment (lead), 3x5 Partners, Adage Capital Management, Arix Bioscience, BioMed Ventures, Lundbeckfonden Ventures, New Enterprise Associates, Pappas Capital, Pfizer, RiverVest Venture Partners
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Non-dilutive funding · 13 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2017	$1.5M
National Institutes of Health (NIH)National Institutes of Health	Phase II	2016	$1.5M
National Institutes of Health (NIH)National Institutes of Health	Phase II	2015	$1.5M
National Institutes of Health (NIH)National Institutes of Health	Phase II	2014	$1.5M
National Institutes of Health (NIH)National Institutes of Health	Phase II	2014	$1.5M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2014	$225K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2013	$696.7K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2013	$599.1K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2012	$697.1K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2012	$580.4K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2012	$558.1K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2012	$301K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2011	$300K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Amplyx do?: Developing a new class of antifungal medicine to overcome limitations of current therapies.
Who are Amplyx's investors?: Amplyx's investors include BioBrit, Golden Seeds, Keiretsu Forum, Pappas Capital, Sofinnova Ventures, 3x5 Partners, Arix Bioscience, Lundbeckfonden Ventures and 3 more.